It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected GC samples and publicly available microarray data and The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV (+) GC. We found that high levels of PD-L1 overexpression in EBV (+) GC were caused by focal amplification of CD274. By contrast, relatively high expression of PD-L1 in tumor tissue and infiltrating immune cells correlated with CD8 lymphocyte infiltration and IFN-γ expression via IRF3 activation. Since we reported previously that PD-L1 expression is associated both with the presence of CD8 T cells in the tumor microenvironment and with IFN-γ expression in GC, we examined a database to see whether IFN-γ-associated overexpression of PD-L1 plays a significant role in EBV (+) GC. Immunohistochemical staining showed that expression of the IRF3 signature in clinical GC samples was higher in EBV (+) than in EBV (−) cases. The data presented herein reveal a unique dual mechanism underlying PD-L1 overexpression in EBV (+) GC: high focal amplification of CD274 or IFN-γ-mediated signaling via activation of IRF3.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Fukushima Medical University School of Medicine, Department of Gastrointestinal Tract Surgery, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540)
2 Fukushima Medical University School of Medicine, Department of Gastrointestinal Tract Surgery, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540); Fukushima Medical University School of Medicine, Department of Medical Electrophysiology, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540)
3 University of Yamanashi, First Department of Surgery, Faculty of Medicine, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
4 Fukushima Medical University School of Medicine, Department of Gastrointestinal Tract Surgery, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540); Fukushima Medical University School of Medicine, Department of Blood Transfusion and Transplantation Immunology, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540)
5 Akita University, Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita, Japan (GRID:grid.251924.9) (ISNI:0000 0001 0725 8504)